IHL-42X Low Dose + IHL-42X High Dose + Placebo + IHL-42X (Optimal Dose) + Dronabinol + Acetazolamide + Placebo
Phase 2/3Active 0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Obstructive Sleep Apnea
Conditions
Obstructive Sleep Apnea
Trial Timeline
May 2, 2024 → Dec 1, 2026
NCT ID
NCT06146101About IHL-42X Low Dose + IHL-42X High Dose + Placebo + IHL-42X (Optimal Dose) + Dronabinol + Acetazolamide + Placebo
IHL-42X Low Dose + IHL-42X High Dose + Placebo + IHL-42X (Optimal Dose) + Dronabinol + Acetazolamide + Placebo is a phase 2/3 stage product being developed by Incannex Healthcare for Obstructive Sleep Apnea. The current trial status is active. This product is registered under clinical trial identifier NCT06146101. Target conditions include Obstructive Sleep Apnea.
What happened to similar drugs?
20 of 20 similar drugs in Obstructive Sleep Apnea were approved
Approved (20) Terminated (2) Active (0)
✅Arformoterol Tartrate Inhalation Solution + Arformoterol Tartrate Inhalation Solution + PlaceboSumitomo PharmaApproved
Hype Score Breakdown
Clinical
15
Activity
12
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06146101 | Phase 2/3 | Active |
Competing Products
20 competing products in Obstructive Sleep Apnea